CD8A and neoplasm: IL-18 is a pleiotropic cytokine, originally identified as an IFN-γ inducing factor, that can modulate anti-tumor responses by promoting the expansion of immune cells that express IL-18 receptor α/β chains including CD8+ T cells, γδ T cells and NK cells.